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day 28, and the costs associated with hospitalization for AUGIB in the UK will be estimated. Consent will be
sought from participants or their representatives according to patient capacity for use of routine hospital data
and day 28 follow up. The study has ethical approval for conduct in England and Scotland. Results will be
analysed according to a pre-deﬁned statistical analysis plan and disseminated in peer reviewed publications
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randomized trial.© 2013 Elsevier Inc. Open access under CC BY license. ACUTE UPPER GASTROINTESTINAL bleeding (AUGIB) is the
commonest reason for emergency hospital admission with a gastro-
intestinal disorder in the UK with an annual incidence of 50 to 150/
100,000 adults [1]. It is the leading indication for red blood cell (RBC)
transfusion, accounting for 14% of all RBCs transfused in England [2].
The purpose of RBC transfusion following AUGIB is to restore regional
and global oxygen delivery. RBC transfusion is life-saving in
exsanguinating patients, but most patients presenting with AUGIB
do not have major hemorrhage, or features of hemodynamic
compromise. In the 2007 UK audit of “AUGIB and the Use of Blood”,
62% of patients had no features of hemodynamic shock [3]. Most cases
of AUGIB, regardless of etiology, will cease without the need for
intervention. Many studies support this notion in that the rates of
endoscopic intervention following AUGIB are in the order of 20-30%
[4,5]. In most cases, RBCs are transfused because the hemoglobin (Hb)
concentration has fallen below a threshold at which the physician
believes the risks of anemia to outweigh the risks of transfusion. This
perception of the appropriate threshold for transfusion is subjective
but is likely to be inﬂuenced bymultiple factors including the desire to
have a “safe”Hb level in the event of re-bleeding, to reduce symptoms
of anemia after bleeding has arrested, or by patient- and clinician-
related factors. Hence, there is considerable practice variation with
respect to RBC transfusion following AUGIB, with rates of transfusion
ranging from 23% to 84% across 208 hospitals in the UK [3].
In other critically ill patient cohorts, a more liberal approach to
transfusion has been associated with adverse clinical outcomes [6].
Two large observational studies have indicated a strong association
between RBC transfusion after AUGIB and the risk of further
bleeding, with a trend towards increased mortality, after adjustment
for confounders [7,8]. These observations have now been supported
by a recently published randomized trial in which rates of mortality
and further bleeding were greater in the liberal transfusion arm [9].
Given the existing uncertainty and variation in transfusion practice
for AUGIB and signals of harm associated with RBC transfusion, it is
vital that the evidence base to inform the safe and effective use of
RBCs is improved.
The purpose of this article is to describe the rationale and protocol
for a cluster randomized controlled feasibility trial in the UK (TRIGGER
—Transfusion in Gastrointestinal Bleeding) which aims to improve the
evidence base for RBC transfusion in AUGIB. We also summarize the
existing evidence and program of preliminary work, which has
justiﬁed the need for and informed the design of the TRIGGER trial.
Summary of Existing Evidence
Evidence for Safe Transfusion Thresholds
Healthy humans can tolerate Hb levels as low as 5 g/dL without
adverse consequences [10] and levels as low as 7 g/dL are safely
tolerated in non-cardiac surgery, intensive care, and trauma patients
[11]. However 13% of patients presenting with AUGIB in the UK have
ischemic heart disease [3], raising concerns about the safe level of
anemia in these patients. There are limited data indicating that
subjects with coronary artery disease may be able to tolerate
moderate normovolemic hemodilution well [12,13]. Lowering theHb threshold for transfusion in patients undergoing coronary artery
bypass surgery from 9 to 8g/dL [14], or from a hematocrit of 30% to
24%, did not result in higher morbidity or mortality [15]. The TRICC
trial, a study comparing restrictive versus liberal RBC transfusion in
intensive care patients, found no difference in mortality through use
of a restrictive transfusion policy (Hb transfusion threshold b7 g/dL)
in a subgroup of 257 patients with known ischemic heart disease [16].
A systematic review of ten randomised controlled trials (RCTs)
comparing clinical outcomes in restrictive versus liberal transfusion
triggers concluded that a restrictive approach led to a 42% reduction in
the probability of receiving transfusions with no effect on mortality,
rates of cardiac events, morbidity, or length of hospital stay [11,17].
Current Guidelines for RBC Transfusion in AUGIB
Current RBC transfusion practices in AUGIB are based upon
consensus opinion. British Society of Gastroenterology guidelines
recommend RBC transfusionwhen the Hb is≤10 g/dL [18], but amore
recent international guideline advocates transfusion when the Hb is
≤7g/dL [19]. For those with AUGIB secondary to portal hypertension,
guidelines recommendmaintaining the Hb around 8g/dL [20], but not
higher. Although some consensus guidelines have advised against the
use of a speciﬁc Hb level as an RBC transfusion trigger, several studies,
mainly in critical care and surgery, have shown that clinicians
attribute considerable importance to the Hb in making transfusion
decisions [21]. This may be a reﬂection of the lack of physiological end
points with sufﬁcient sensitivity and speciﬁcity to guide transfusion
decisions, especially outside a critical care setting.
Sources of Harm and Cost of RBC Transfusion
Over the past decade there has been a marked change in critical
care and surgical transfusion practice with an increased appreciation
of the potentially harmful effects of allogeneic blood transfusion.
Research in intensive care [22], cardiac surgery [23], and coronary
care [24] suggest associations between blood transfusion and adverse
patient outcomes, including death, even after adjustment for known
confounders. Potential sources of harm from RBCs are poorly
understood [25]. Some, such as transfusion-transmitted infection,
transfusion-related acute lung injury, and hemolytic reactions are
well deﬁned but rare; transfusion-associated circulatory overload is
unlikely to be rare but rather under-reported. Other possible
mechanisms of harm include (1) adverse effects resulting from
changes to RBCs that occur during blood storage [26]; (2) pro-
inﬂammatory effects of blood transfusion [27] and; (3) transfusion of
donor leukocytes, although the implementation of universal pre-
storage leukocyte-reduction of blood components has reduced this
risk [28].
Speciﬁc to AUGIB, the mechanism by which transfusion may be
associated with further bleeding is unclear. In those patients with
cirrhosis and portal hypertension who bleed from varices, excessive
RBC transfusion is likely to worsen portal hypertension through
volume overload, although it is possible that these effects may also
occurwith excessive ﬂuid infusion per se as opposed to a unique effect
of RBCs. However, this does not explain the mechanism in the
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variceal in origin (approx 90%). One postulated mechanism is that
transfusion could counteract the splanchnic vasoconstrictive response
after hypovolemic hemorrhage, resulting in a rebound increase in
splanchnic blood pressure which could impair the ability to form clots
[9]. It is unlikely that RBC transfusion would adversely impact upon
the coagulation cascade to impair hemostasis. The mechanism of
increased mortality with more liberal transfusion is most likely
mediated through an excess of further bleeding, since this event is a
strong and independent predictor of death [29].
Preliminary Work to Inform the TRIGGER Trial
The 2007 UK National Audit of AUGIB and the Use of Blood
This study provided detailed, “real-life” outcome data from 6750
patients with AUGIB admitted across 208 UK hospitals over a 2-month
period [3,30]. The study highlighted areas of signiﬁcant variation in
transfusion practice and inappropriate use of RBCs; for example, 15%
of all RBCs were transfused to patients with a Hb N10 g/dL, who were
hemodynamically stable. There was substantial clinical uncertainty in
transfusion practice in patients presenting with a Hb between 8.1–10
g/dL. In this Hb range 51% of patients received transfusion and 49% did
not. When patients were then stratiﬁed by the absence/presence of
hemodynamic abnormality, the variability persisted. This range
represents a genuine area of clinical uncertainty, practice variation,
and potential equipoise in the RBC transfusionmanagement of AUGIB.
Outcomes Following Early RBC Transfusion for Acute Upper
Gastrointestinal Bleeding
The relationship between early RBC transfusion, further bleeding,
and mortality following AUGIB in 4,441 patients from the national
audit data-set was examined. After adjusting for the clinical Rockall
score [31] and initial Hb, early RBC transfusionwas associatedwith a 2-
fold increased risk of further bleeding (OR, 2.26; 95% CI 1.76-2.90) and
a 28% increase inmortality (OR 1.28; 95% CI 0.94-1.74) [7]. Remarkably
similar results were observed in a Canadian study of 1677 cases of
AUGIB [8]. These studies suggest that many patients presenting with a
Hb of N8 g/dL following AUGIB may not beneﬁt from transfusion, and
could be harmed. Whilst these results do not prove a causal
relationship, they indicate that a randomized comparison of restrictive
and liberal transfusion policies in AUGIB is justiﬁed to conﬁrmor refute
the ﬁndings of these observational studies.
A National Survey of Clinicians
A survey of UK clinicians was conducted with the aim of
characterizing and understanding attitudes towards transfusion
practice in patients with AUGIB [32]. Clinicians were asked to select
a Hb threshold at which they would ordinarily transfuse RBCs in 6
realistic scenarios of AUGIB, and 815 clinicians responded. The most
important patient characteristic raising the transfusion threshold was
the presence of ischemic heart disease. The overall responses
suggested belief that restrictive use of RBCs is appropriate, but were
discordant with the observed practice in the national audit highlight-
ing the discrepancy between theory and practice.
A Systematic Review of Randomized Controlled Trials
A Cochrane systematic reviewwas conducted in 2008 and updated
in 2010 [33]. Only 3 small randomized controlled trials investigating
differing RBC transfusion strategies in patients with AUGIB (total of 93
patients across 3 trials) were identiﬁed and all had methodological
deﬁciencies. Whilst there was a trend towards increased mortality
and further bleeding in the transfusion arms of the combined studies,the small number of participants and the large volume of missing data
limited the generalizability of the ﬁndings. These data further support
the need for a deﬁnitive randomized controlled trial to establish the
risks and beneﬁts of RBC transfusion in this population. The
publication of a large trial subsequent to this Cochrane review will
lead to an update of the review and a more precise estimate of
treatment effects [9].Patients and Methods
Trial Objectives
The objective of the TRIGGER trial is to evaluate the feasibility and
safety of implementing a restrictive versus a liberal RBC transfusion
policy in adult patients admitted with AUGIB, in order to inform the
design of a deﬁnitive phase III trial.
Design and Setting
TRIGGER is a pragmatic, cluster randomized feasibility trial
comparing 2 different RBC transfusion strategies in patients admitted
with AUGIB. Each participating center will be randomly allocated to
one of 2 transfusion policies, and all eligible patients in a centre will be
treated according to the allocated transfusion policy. The trial will
recruit in 6 academic centers in the UK. Both feasibility and clinical
outcome measures will be collected. Feasibility measures include
recruitment rate, adherence to the transfusion policy, the difference in
Hb, and RBC exposure between the restrictive and liberal transfusion
policies and evidence of selection bias. Clinical outcomes include
further bleeding, mortality, need for therapeutic endoscopy, need for
surgery or radiological intervention to control bleeding, thromboem-
bolic, and ischemic events, infections, transfusion reactions, and an
assessment of quality of life at day 28 (EuroQol EQ-5D). Data will also
be gathered to identify factors leading to contravention of the
transfusion policy, and to enhance estimates of the intraclass
correlation coefﬁcient (ICC) to inform the sample size calculation for
a phase III cluster randomized trial. The full trial protocol is available on
the dedicated trial Web site: http://www.trigger.nhsbt.nhs.uk/.Randomization of Clusters
Widespread consultation was conducted amongst clinical stake-
holders in each potential center to ensure a willingness to be
randomized to either transfusion policy and agreement to implement
the allocated policy on a hospital wide level. Centers will be
randomized using permuted blocks without stratiﬁcation or match-
ing, in order to ensure an equal number of centers are assigned to each
transfusion policy. Recruitment of patients will operate for 6 months
in total in each center.Eligibility Criteria
Eligibility criteria relate both to those of the cluster and to the
individual trial participants. Clusters (ie, hospitals) are eligible to take
part if they meet the following criteria:
• N20 admissions with AUGIB per month
• 400 hospital beds
• Availability of 24 hour endoscopy and on-site access to intensive
care and surgical support
• Willingness to be randomly allocated to a transfusion policy
• Institutional agreement to transfuse all eligible new admissions
with AUGIB in accordancewith the randomized transfusion policy
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• They are aged ≥18 years presenting to hospital with AUGIB,
deﬁned as hematemesis or the passage of melena.
Participants are not eligible to take part in the study if:
• The responsible clinician considers there is a need for immediate
RBC transfusion prior to obtaining or regardless of the initial Hb
result due to severity of bleeding.
• They are an existing hospitalized patient who subsequently
develops AUGIB.
No upper age limit has been set for patient level inclusion criteria.
In the large UK audit of AUGIB, 28% of presentations were aged ≥80
years (1898/6750) and excluding this group would limit both the
anticipated recruitment rate and generalizability of the trial ﬁndings.
Whilst the assessment of severe bleeding is left to clinical judgment,
additional pragmatic guidance include (but are not exclusive to)
patients with features of hemodynamic shock (systolic BP b100
mmHg and/or heart rate N100 bpm) and receipt of RBCs within 2
hours of presentation, transfusion of emergency O-negative blood, or
performance of the index endoscopy in an emergency clinical area due
to severity of bleeding.
Interventions
The trial will compare 2 different policies for RBC transfusion,
“restrictive” and “liberal”. All eligible patients admitted to a
participating site should be transfused in accordance with the
randomized transfusion policy.
Restrictive Transfusion Policy (RBCs Transfused When Hb ≤8 g/dL)
If the Hb value is recorded as≤8.0 g/dL, RBCs should be transfused
with the aim of keeping the Hb range between 8.1 and 10.0 g/dL.
Further RBC transfusions should only be administered if the Hb value
decreases to a value of 8.0g/dL or less.
Liberal Transfusion Policy (RBCs Transfused When Hb ≤10 g/dL)
If the Hb value is recorded as ≤10.0 g/dL, RBCs should be
transfused with the aim of keeping the Hb range between 10.1 and
12.0 g/dL. Further RBC transfusions should only be administered if the
Hb value decreases to a value of 10.0 g/dL or less.
In both intervention arms the number of RBC units transfused and
the timing of repeat Hb measurements will be decided by the caring
clinician. Any transfusion(s) required as part of the policy should be
administered within 24 hours of obtaining the Hb result.
Clinician Discretion to Transfuse in Contravention of the Allocated Policy
All clinicians will have the discretion to transfuse, or not to
transfuse, in contravention of the allocated policy for any patient
admitted with AUGIB. Any clinician who deviates from the policy will
be asked to provide the reason(s) for doing so on a Case Report Form.
This is not designed to challenge the clinician’s judgment, but rather
to identify patient subgroups, whichmay not be feasible to recruit into
the planned phase III trial. Possible reasons for additional transfusions
outside of the protocol could include periods of further bleeding or
hemodynamic instability.
Outcomes
The study will collect a range of feasibility outcome measures and
clinical outcome measures.
Feasibility outcome measures for each treatment arm include:
• The proportion of eligible patients who provide consent.
• The proportion of patients who are ineligible due to need for
immediate transfusion.• Protocol adherence, which includes:
1. Overall adherence: the proportion of Hb counts for each patient
where no deviation occurred. This will be averaged across all
patients.
2. Adherence per Hb count: the overall proportion of Hb counts
where no deviation occurred.
3. Adherence per patient: the proportion of enrolled patients for
whom no transfusion deviation occurred.
• Selection bias: As the study is open-label, all clinicians will be
aware of their hospital’s transfusion policy, resulting in the
possibility of selection bias. The following outcomes will be
compared between the 2 interventional arms in order to
investigate this:
o Age, shock, Hb at baseline, clinical Rockall score, Blatchford
score, and the number of major comorbidities for consented
patients
o The difference in the baseline Hb, Rockall and Blatchford
scores of consented vs. those not consented
• The number of RBC units transfused
• The proportion of patients receiving at least one RBC transfusion.
• The mean Hb over the ﬁrst 7 days after admission
• The mean Hb over the entire study period (i.e. up to discharge/
death/28 days)
• The mean Hb on discharge (the last recorded Hb prior to
discharge will be used)
Clinical outcome measures include:
• Further bleeding up to day 28: further bleeding is a composite
outcome that includes persistent bleeding and recurrent bleed-
ing. Recurrent bleeding should initially be suspected in the event
of any combination of the following: fresh hematemesis,
continuous melena, or aspiration of fresh blood from a
nasogastric tube, with a pulse rate of N100 bpm, a fall in systolic
blood pressure of N30 mm Hg or a drop in Hb of N2g/dL in the
preceding 24 hours.
• Further bleeding up to hospital discharge
• All-cause mortality up to day 28.
• All-cause mortality up to hospital discharge
• Therapeutic intervention at the index endoscopy
• Surgical or radiological intervention to control bleeding up to
death/discharge
• Proportion of patients experiencing the composite end point of
thromboembolic and ischemic events up to Day 28. This is
composed of myocardial infarction, stroke, pulmonary embolus,
DVT, and acute kidney injury. Each component will also be
assessed individually.
• Proportion of patients experiencing the composite end point of
thromboembolic and ischemic events up to hospital discharge
• Acute transfusion reactions up to death/discharge. This is
deﬁned as a reaction occurring at any time up to 24 hours
following a transfusion of a blood component.
• Infection up to day 28. This is deﬁned as any infection
necessitating a prescription for antibiotic treatment for a
minimum of 5 days, provided the prescription is received before
or on day 28
• Infection up to hospital discharge
• Length of hospital stay
• Health related quality of life at Day 28 (using EuroQol EQ-5D).
• Serious adverse events up to day 28.
Participant Screening and Selection
Potential trial participants will be identiﬁed from Emergency
Departments (ED) or Medical Admissions Units (MAU) from
September 2012 until February 2013. All eligible patients will be
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policy, from presentation up to discharge. This will be facilitated
through extensive education of clinical staff in acute admission areas,
display of treatment algorithms in relevant clinical areas and a simple
ﬂagging system in blood banks to remind doctors of the hospital’s
transfusion policy whenever a transfusion request for AUGIB occurs.
The trial research nurse/member of the research team will screen
admission lists daily and will be encouraged to have a strong presence
in the emergency admissions area(s) to ensure admissions with
AUGIB are identiﬁed daily. All eligible patients will be approached as
soon as possible after presentation with AUGIB to obtain informed
consent. All patients who provide written informed consent for data
collection and follow-up at Day 28 will count as enrolments to the
study. A schema of enrolment procedures is outlined in Figure.Intervention
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to provide consent. However, some patients may lack capacity to
provide consent or have ﬂuctuating capacity; in these cases guidance
is provided by the Mental Capacity Act (England and NI; 2005) and
Adults with Incapacity Act (Scotland; 2000).Consumer Involvement
We formed a TRIGGER trial focus group comprising members of
the Patient Panel from the John Radcliffe Hospital, Oxford. Some
members of this group had suffered from AUGIB and had received
blood transfusions in the past. We discussedwith the panel the ethical
issues involved in the consent process and the complexities involved
in cluster randomization. Two face-to-face focus groups with 9
members of the panel were conducted and involved an educational
seminar about AUGIB and clinical trials.
We used a mixture of both qualitative and quantitative methods of
feedback and all participants completed an anonymous questionnaire.
All participants supported (as indicated both in the discussion and
anonymous feedback forms) the consent processes outlined. Specif-
ically they unanimously supported the notion of automatic treatment
of eligible patients with the hospital’s allocated transfusion policy
without the need to obtain patient consent for the intervention, given
the existing variation in transfusion practice we have demonstrated
throughout the UK and the fact that both policies are within current
practice. However, they stressed that all clinicians involved in the
patient’s care should have the discretion to transfuse in contravention
of the policy if they wish to do so, such that patient safety is not
compromised. Members of the panel also helped to inform the
content of the information sheets and consent forms. A similar process
was conducted with a patient group through Age UK and the
summaries of these meetings helped to inform our ethics application.Sample Size
As this is a feasibility study, no formal sample size calculation was
undertaken to determine the number of patients required based upon
a primary end point. Using information on the number of admissions
with AUGIB at each participating centre, we estimated 1062 eligible
patients would present over the course of 6 months. Assuming an 80%
consent rate, this would give 849 patients enrolled in total.
This feasibility study will also help to inform the sample size
calculation for the deﬁnitive phase III trial by allowing estimates of the
rate and ICC for further bleeding, which is likely to form the primary
outcome of the phase III trial.
TRIGGER is not powered on the end-points of further bleeding or
mortality. However safety is being monitored by review of serious
adverse events by an independent datamonitoring committee. Any large
imbalances between treatments that suggest harm would inﬂuence the
feasibility of a larger followon trial, as is the case in all early phase studies.
Data Collection
Screening Log
A daily screening log of all patients admitted with AUGIB will
record the total number of admissions, the number meeting eligibility
criteria and eligible patients enrolled in each hospital. Anonymized,
baseline clinical characteristics for each patient will be recorded.
Baseline Characteristics
Baseline clinical characteristics will be obtained from routine
patient records and will include age, gender, presenting symptoms,
routine physiological parameters, Rockall and Blatchford score [37]
and use of anti-platelets/anticoagulants.Laboratory and Transfusion Data
The date and time of all Hb measurements will be recorded as well
as the ﬁrst coagulation screen, liver function test, and biochemistry
proﬁle. All RBC transfusion episodes will be recorded including the Hb
level prior to transfusion and the total number of RBC units
transfused. The number of other blood components administered
including fresh frozen plasma and platelets will be recorded.
Endoscopic and Pharmacological Data
Endoscopic data will include date and time of endoscopy,
endoscopic diagnosis, stigmata of hemorrhage, and nature of
therapeutic procedure. Pharmacological data will include use of
proton pump inhibitors before and after endoscopy and the use of
antibiotics and vasopressors for patients with variceal hemorrhage.
Day 28 Follow-Up
Day 28 follow-up will be conducted by telephone to assess a list of
pre-deﬁned clinical outcomes, quality of life (QoL), and resource use
details. The patient’s primary care physician will ﬁrst be telephoned
to ascertain survival status before calling the patient. A telephone
version of the EQ-5D questionnaire will be used to assess QoL. For
patients who are still in hospital at Day 28 this will be conducted
face-to-face.
Data Management
All data will be recorded on paper case report forms. Centers
will send copies of completed case report forms to the data
manager at the NHS Blood and Transplant Clinical Studies Unit,
where they will be entered onto a bespoke trial database designed
using the MACRO v3.2 clinical trial software management system
supplied by InferMed Limited.
Data Analysis
All analyses will be described in full detail in a Statistical Analysis
Plan, which will be ﬁnalized prior to data lock and analysis. Outcomes
will be analyzed using cluster level summaries which will account for
the correlation between patients in the same center. For feasibility
outcomes, all enrolled patients will be included in the analysis. For
clinical outcomes, the primary analysis will only include patients
whose Hb dropped below 12 g/dL during the follow up period. This is
to restrict the clinical analysis to those patients who are likely to have
been affected by the transfusion policy. A cut-off of 12 g/dL was
selected to ensure the majority of transfused patients will be included
in the analysis. A secondary analysis of clinical outcomes will include
all patients.
For the main trial, the primary outcome is likely to be further
bleeding. The ICC for further bleeding estimated from this feasibility
study will be imprecise, as it will be based on only 6 centers. In order
to obtain a more precise estimate of the ICC on which to base the
sample size for the main trial, the ICC from the feasibility study will be
combined with the ICC obtained using observational data from the
national audit of AUGIB.
Health Economics
Health economics will be incorporated in to the feasibility trial in 2
ways. Firstly, the feasibility of gathering data required to facilitate a
cost-effectiveness analysis (eg, resource use, costs, outcomes) will be
examined to inform data collection for a phase III trial. Secondly, the
feasibility of using these data within a cost-effectiveness model will
be explored to identify parameters with the potential to be key
drivers of cost-effectiveness, and hence requiring detailed measure-
ment in the planned phase III trial. Within this feasibility trial, costs
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for the ﬁrst time.
Ethics
The trial received favorable ethical opinion from the NRES
Committee South Central- Oxford C, REC reference 12/SC/0062 for
conduct in England and by the Scotland A Research Ethics Committee
for conduct in Scotland, REC reference 12/SS/0023. Site speciﬁc R&D
department approvals will be obtained in each recruiting site in
England and Scotland. The trial registration number is ISRCTN:
85757829 and the trial is registered on the NIHR Clinical Research
Network (Study ID: 12078 Oral and Gastrointestinal, co-adopted by
Blood, Injuries and Emergencies).
Trial Management
The Trial Management Groupwill be responsible for the day to day
conduct of the trial. An independent Trial Steering Committee (TSC)
will provide overall supervision for the trial and provide advice to the
Trial Management Group through its independent Chair. Other
members of the TSC will include 2 independent clinicians and a lay
representative. The ultimate decision for the continuation of the trial
lies with the TSC. A core independent Data Monitoring Committee
(IDMC) will monitor safety, progress, and quality of the trial. The
composition of the committee is detailed in the study protocol, which
is available on the trial website (http://www.nhsbt.nhs.uk/trigger/).
The trial is being coordinated through the NHS Blood and Transplant
Clinical Studies Unit/MRC Clinical Trials Unit.
New Evidence Which Has Arisen During the Conduct of TRIGGER
At the time of submission of this manuscript, new evidence has
arisen from a single centre RCT in a specialist gastrointestinal bleeding
unit in Barcelona indicating beneﬁt of a restrictive approach to
transfusion in patients with AUGIB [9]. Over a 6-year period from
2003–2009 this RCT enrolled 39% (921/2372) of presentations with
AUGIB into a trial of restrictive (eligible for transfusion when Hb b7 g/
dL to maintain Hb at 7–9 g/dL; n = 461) versus liberal (eligible for
transfusion when Hb b9 g/dL to maintain Hb at 9–11 g/dL; n = 460)
RBC transfusion strategies. The rates of further bleeding were
signiﬁcantly lower in the restrictive transfusion arm (10% vs 16%)
and 45 day mortality was also lower in the restrictive transfusion arm
(5% vs 9%). The overall adverse event rate was higher in the liberal
transfusion arm (48% vs 40%), the key differences being an increase in
transfusion associated circulatory overload and transfusion reactions
in the liberal arm.
Aside from the transfusion thresholds and randomization meth-
odology, there are a number of important differences between
TRIGGER and the Villanueva trial. Firstly, the patient population
differs from the population which will be expected in TRIGGER. In
particular: (1) 31% of patients in the Villanueva study had liver
cirrhosis while this ﬁgure is likely to be b10% in TRIGGER; (2)
TRIGGER will include patients with ischemic heart disease and
cardiovascular disease, stroke, and peripheral vasculopathy, which
were notable exclusions in the Villanueva study. These are important
to consider when extrapolating the ﬁndings of the results (ie, the
trial’s external validity); (3) the Villanueva trial did not show any
beneﬁt for the restrictive policy in patients with peptic ulcer bleeding
who are likely to form the largest group in TRIGGER, based upon UK
epidemiology; and 4) the external validity of the Villanueva trial is
limited as it arises from a single tertiary centre with strict protocols of
care administered to all patients in the trial, which may not reﬂect
routine care in most healthcare institutions e.g. the ability to provide
therapeutic endoscopy within 6 hours for all patients no matter whattime or day they are admitted, since the availability of such an
intervention may in turn inﬂuence thresholds for transfusion.
The Villanueva trial was published after 75% of recruitment for
TRIGGER was completed. The availability of this new external
evidence had the potential to inﬂuence the conduct and methodology
for the remainder of recruitment. All recruiting sites were contacted
within 24 hours of publication of the Villanueva trial to discuss the
trial ﬁndings and after local discussions they all expressed a
willingness to continue recruitment to TRIGGER. Indeed, in view of
the highlighted differences between the studies and the limited
external validity of the Villanueva study, it was felt to be even more
important to produce further evidence to conﬁrm or refute the
ﬁndings of the Villanueva trial. In addition we contacted the ethics
committee, IDMC, and TSC following publication of the Villanueva
study. The IDMC performed an unscheduled review of serious adverse
events, mortality, and further bleeding. Based on the results of this
unscheduled review, and in light of the differences between the 2
trials, they recommended continuation of TRIGGER. All independent
members of the TSC recommended that we continue the trial for
similar reasons. Whilst the Villanueva trial adds important new
information to this subject area, further pragmatic trials are
warranted and the design of TRIGGER will both help to inform this
debate as well as address some of the limitations of the trial.
Discussion
In the UK, an estimated 350,000 units of RBCs are administered
annually to patients with AUGIB, making it the most common single
indication for transfusion of RBCs. The direct costs are approximately
£45.5 million for the blood alone, which does not take into account
costs associated with administration, patient monitoring, and man-
aging adverse events. The preliminary work leading up to this trial
identiﬁed a lack of evidence informing the RBC transfusion manage-
ment of AUGIB, and widely varying use of RBC transfusion amongst
UK clinicians including evidence of liberal approaches to transfusion.
Two large observational studies found an independent association
between RBC transfusion and adverse clinical outcome, notably an
increased risk of further bleeding [7,8], and a recent randomised trial
[9] reported an increase in further bleeding and mortality with a
liberal transfusion policy. Further bleeding is of clinical importance
since this one of the most important predictors of mortality, and
further bleeding rates have not improved in longitudinal UK data over
the past 15 years [29], despite advances in endoscopic therapy. Taken
together, these observations support the need for an RCT comparing
different RBC transfusion strategies in AUGIB in order to inform the
safe and effective use of RBC transfusion.
Conducting an RCT of RBC transfusion strategies in patients with
AUGIB is challenging. AUGIB is a medical emergency, where the
majority of patients are admitted out of normal working hours and
there is often a need for early administration of blood components. In
the UK, patients are usually managed in several different clinical areas
within hours of presentation, under the care of a broad range of
clinicians from different teams (including EmergencyMedicine, Acute
Medicine, and Gastroenterology). With these challenges in mind, the
TRIGGER trial has been designed to assess the feasibility and safety of
implementing a restrictive versus liberal RBC transfusion policy in
adult patients admitted with AUGIB.
The methodology of the trial was carefully considered after wide
ranging consultation with frontline clinicians, clinical trialists,
methodologists, and patient groups. Cluster randomization was
deemed to be the most appropriate methodology to address some
of the aforementioned challenges and in addition to avoid the high
perceived risk of contamination between interventions if individual
randomization was used. The feasibility end points of the trial will
help to establish whether a broad range of clinicians can sufﬁciently
adhere to a transfusion policy in order to justify a follow on phase III
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point upon which to power the trial.
Whilst a more restrictive approach to transfusion has been
demonstrated to be as safe [11], or in some circumstances, superior
to a liberal transfusion policy [6], it is important to note that very few
of these studies have been conducted in the setting of patients
presenting to hospital with acute hemorrhage. Indeed, any history of
bleeding was an exclusion criterion in a RCT of 2 differing RBC
transfusion strategies in critically ill patients [6]. The transfusion
thresholds chosen in the TRIGGER interventional arms are based on
modeling using a large observational dataset of actual transfusion
practice in the UK and are within the recommendations included in
UK national and local clinical guidelines. Importantly, all clinicians
taking part in the trial have the discretion to transfuse, or refuse to
transfuse, outside of the policy that their hospital has been allocated
by cluster randomization. The reasons for protocol violations are
being recorded and thesemay help to further inform eligibility criteria
for a phase III trial.
RBCs are a costly, ﬁnite, and scarce resource. Improving the
evidence base for their safe and effective use is of major public health
importance. The TRIGGER trial will begin to inform the evidence base
for the leading indication for RBC transfusion in the UK. Uniquely, it
will also provide an estimate of the costs associated with hospital-
ization for AUGIB in the UK, and assess health related quality of life at
28 days post presentation. The study will inﬂuence the wider debate
about restrictive prescribing of blood products and the utilization of
both blood conservation and avoidance strategies in other clinical
settings. The results of the study will inform the feasibility and design
of a larger phase III trial.
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